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In this issue of Immunity, Hermann-Kleiter et al. (2008) identify a nuclear orphan receptor, NR2F6, as
a negative regulator of the T helper 17 cell subset and report that NR2F6-deficient mice develop late-onset
autoimmune disease.CD4+ T helper cells are important in
orchestrating appropriate immune re-
sponses to the diverse pathogens en-
countered during a person’s or animal’s
lifetime. Upon antigen recognition, these
cells differentiate into different subsets
that produce signature cytokines. IFN-g
is produced by T helper 1 (Th1) cells,
which combat intracellular pathogens
such as viruses, and IL-4, IL-5, and IL-13
are produced by Th2 cells, which defend
against extracellular bacteria and large
parasites. A third subset, denoted Th17
cells because of its characteristic produc-
tion of proinflammatory cytokine IL-17,
has been suggested to have a critical
role in fighting fungal and parasitic infec-
tions (Milner et al., 2008). In this issue of
Immunity, Hermann-Kleiter et al. (2008)
identify the orphan nuclear receptor
NR2F6 as a negative regulator of IL-17
production by T cells (Figure 1).
The pathways that drive the differentia-
tion of naive CD4+ T cells into IL-17-pro-
ducing Th17 cells are relatively well
understood. Two cytokines, IL-6 and
TGF-b, cooperate to induce Th17 cell dif-
ferentiation (Dong, 2008; Ivanov et al.,
2007). The precise role of TGF-b remains
unclear, but IL-6 stimulation leads to acti-
vation of the downstream transcription
factor STAT3 and subsequent induction
of two closely related ‘‘orphan’’ nuclear
receptors, RORa (NR1F1) and RORgt (a
splice variant of NR1F3). These proteins
(both members of the nuclear receptor
subfamily 1F) are termed ‘‘orphan’’ recep-
tors because physiological ligands that
activate them (such as retinoic acid for
the RAR-NR1B family) have not yet been
identified. Genetic ablation and overex-
pression studies have demonstrated that
both RORa and RORgt participate in
Th17 cell differentiation (Dong, 2008;
Ivanov et al., 2007). As such, they are
key transcriptional regulators of Th17 celldevelopment, analogous to T-bet and
GATA-3, which drive Th1 and Th2 cell
differentiation, respectively.
Less is known about mechanisms that
might blunt IL-17 production during an im-
mune response or turn off its expression
once a pathogen is cleared. IL-2, a critical
growth factor for T cells, limits Th17 cell
differentiation and IL-17 production via
activation of the transcription factor
STAT5 (Laurence et al., 2007). Other cyto-
kines, including IFN-g, IL-4, and IL-27, are
also known to diminish cytokine produc-
tion by Th17 cells (Dong, 2008; Ivanov
et al., 2007). Cytokines are external
cues; cell-intrinsic negative-feedback
mechanisms that curtail IL-17 production
have not yet been identified. It is in this
context that the report by Hermann-
Kleiter et al. (2008) provides novel
insights.
NR2F6 is a transcriptional repressor
with a role in neural development (War-
necke et al., 2005). It caught the attention
of Hermann-Kleiter et al. (2008) when they
identified it as a potential substrate of the
protein kinase C (PKC) family by using
a robust predictive approach that had
been validated for PKCz and PKCd (Fujii
et al., 2004). Indeed, several PKC family
members—PKCa, PKCd and PKCq—
were shown to phosphorylate a GST-
NR2F6 fusion protein at the predicted
phosphorylation site, serine-83, in vitro.
Immunoblotting with a phosphorylation-
site-specific antibody confirmed that the
same site was phosphorylated in Jurkat
cells stimulated with the phorbol ester
PDBu, which actives several PKC family
members. Functionally, phosphorylation
did not appear to alter the constitutive nu-
clear localization of NR2F6, because an
NR2F6-GFP fusion protein remained nu-
clear for several hours after stimulation
of Jurkat T cells with staphylococcus
enterotoxin E (SEE)-pulsed B cells.Immunity 2However, phosphorylation appeared to
inhibit the DNA-binding ability of NR2F6
(Figure 1). This latter conclusion was not
direct, however, but rather was based
on the finding that substitution of the
PKC target residue serine-83 with gluta-
mate diminished the ability of NR2F6,
obtained from nuclear extracts of trans-
fected Jurkat cells, to bind DNA in vitro.
Strangely, robust DNA binding could
only be observed when an antibody to
NR2F6 was added to the nuclear extracts.
Note that if PKC indeed phosphorylates
NR2F6 directly, some translocation event
must be involved, such as movement of
PKC to the nucleus, where NR2F6 is local-
ized, or of NR2F6 to the plasma mem-
brane, where the bulk of active PKC is
found.
The evidence that NR2F6 might be a
T cell-intrinsic negative regulator of IL-17
production derives primarily from analysis
of NF2R6-deficient mice. Nr2f6/ mice
examined at 12 months of age exhibited
splenomegaly, had elevated serum levels
of IgG1 and IgE, and displayed a late-
onset lupus-like autoimmune disease as
judged by the presence of anti-nuclear
antibodies and other circulating autoanti-
bodies. T cells from Nr2f6/ mice
showed substantially increased produc-
tion of IL-2; the mechanism appears to
be T cell intrinsic rather than merely
reflecting alterations in T cell develop-
ment because a similar decrease was
observed in wild-type T cells treated
with siRNA to deplete NR2F6. Nr2f6/
T cells also displayed a substantial (2-
fold) increase in IL-17 production after
culture under Th17 cell-inducing condi-
tions. Consistent with the augmented
production of IL-17 by cultured T cells,
the Nr2f6/ mice were hypersusceptible
to the induction of experimental autoim-
mune encephalomyelitis (EAE), although
the clinical EAE scores attained were9, August 15, 2008 ª2008 Elsevier Inc. 167
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Previewsvery low. This phenotype is consistent
with that expected of mice overexpress-
ing IL-17, a proinflammatory cytokine
that is known to underlie the pathogenesis
of several inflammatory and autoimmune
disorders including systemic lupus eryth-
Figure 1. Regulation of Cytokine Secretion
by NR2F6 Phosphorylation
(Top) In the absence of stimulation, NR2F6 is not
phosphorylated and is postulated to bind DNA
and regulate the expression of target genes that
are still to be identified. However, in stimulated
T cells, NR2F6 is phosphorylated by activated
PKC (bottom) through an unknown mechanism
that would require PKC translocation into the nu-
cleus or transient movement of NR2F6 into the cy-
toplasm. Phosphorylation of NR2F6 is postulated
to diminish its DNA binding. In stimulated cells,
NFAT mediates the transcription of Il2 and Il17.
By inhibiting NFAT-driven IL-2 and IL-17 produc-
tion, NR2F6 may contribute to regulating cytokine
secretion to maintain an appropriate balance
between fungal clearance and autoimmunity.168 Immunity 29, August 15, 2008 ª2008 Eematosis, arthritis, and asthma (Korn
et al., 2007). The results suggest that
NR2F6 contributes to maintaining im-
mune activation at a balanced and
appropriate level, thereby preventing
immune-mediated inflammation and
autoimmune disease.
How might NR2F6 repress IL-2 and
IL-17 production in wild-type T cells? The
study does not fully clarify this issue. The
authors favor an indirect mechanism that
involves repression of the transcription
factor NFAT, a well-established positive
regulator of Il2 and Il17 transcription (Liu
et al., 2004; Hogan et al., 2003). Over-
expression of wild-type NR2F6 led to
a 50% decrease in the activity of an
NFAT-dependent reporter in Jurkat
T cells, whereas overexpression of the
S93E mutant (presumed to be deficient in
DNA binding) did not. Moreover, nuclear
extracts of Nr2f6/ T cells consistently
showed increased NFAT DNA-binding ac-
tivity and a somewhat less consistent in-
crease in AP-1 DNA-binding activity. A
puzzling aspect of this hypothesis, how-
ever, is that NR2F6 deficiency did not
affect the expression of other known
NFAT-dependent genes, particularly inter-
feron-g (IFN-g). The increase in NFAT
DNA-binding in Nr2f6/ T cells was not
accompanied by any obvious change in
the phosphorylation status or nuclear
translocation of NFAT; however, because
the fraction of NFAT in the nucleus at any
given time is determined by the balance
between nuclear import and export, it will
be important to determine the kinetics of
NFAT nuclear transport in wild-type and
Nr2f6/ T cells to establish this point
definitively.
An alternative mechanism for NR2F6-
mediated gene repression invokes its
ability to bind to DNA. NR2F6 may repress
transcription of the Il2 and Il17 genes by
binding directly to the regulatory regions
of these genes. This point could readily
be addressed by bioinformatic analysis
to identify putative conserved regulatory
regions and NR2F6-binding elements,
followed by chromatin immunoprecipita-
tion (ChIP) assays to examine whether
NR2F6 is associated with these elements
in resting cells. NR2F6 may also act indi-lsevier Inc.rectly to modulate the expression of tran-
scriptional regulators that affect Il2 and
Il17 expression, a hypothesis that could
be investigated through a combination of
transcriptional profiling and genome-
wide ChIP assays.
Does NR2F6 serve to prevent inappro-
priate activation of resting T cells, or
does it rather limit cytokine production
during the period of ongoing activation?
Given that NR2F6 is expressed in resting
T cells and is downregulated upon activa-
tion, it seems unlikely that it would control
the duration of cytokine production by ac-
tivated T cells. In contrast, the overt auto-
immune pathology seen in older Nr2f6/
mice suggests a dominant role of NR2F6
in limiting unwarranted inflammation.
Identifying the transcriptional targets of
NR2F6, as well as the various signaling
molecules that modulate its expression
and function, would greatly advance
our understanding of how this transcrip-
tional regulator contributes to repressing
inflammation and autoimmune disease.
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